Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$25.57+1.34 (+5.53%)
Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –
Veracyte operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Veracyte's operating income for the twelve months ending Jun 30, 2026 was $105.77M, up 664.9% year over year. For fiscal 2025 it was $57.78M, up 257.9% from the year before. The highest annual figure on record is $57.78M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.78M | +257.9% |
| FY2024 | Dec 31, 2024 | $16.14M | – |
| FY2023 | Dec 31, 2023 | -$85.80M | – |
| FY2022 | Dec 31, 2022 | -$41.08M | – |
| FY2021 | Dec 31, 2021 | -$81.90M | – |
| FY2020 | Dec 31, 2020 | -$35.39M | – |
| FY2019 | Dec 31, 2019 | -$15.13M | – |
| FY2018 | Dec 31, 2018 | -$22.23M | – |
| FY2017 | Dec 31, 2017 | -$26.54M | – |
| FY2016 | Dec 31, 2016 | -$28.80M | – |
| FY2015 | Dec 31, 2015 | -$33.47M | – |
| FY2014 | Dec 31, 2014 | -$29.01M | – |
| FY2013 | Dec 31, 2013 | -$23.17M | – |
| FY2012 | Dec 31, 2012 | -$18.93M | – |
| FY2011 | Dec 31, 2011 | -$15.27M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.98M | – |
| Q1 FY2026 | Mar 31, 2026 | $22.65M | +679.8% |
| Q4 FY2025 | Dec 31, 2025 | $37.20M | +790.9% |
| Q3 FY2025 | Sep 30, 2025 | $22.95M | +90.9% |
| Q2 FY2025 | Jun 30, 2025 | -$5.27M | -214.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.90M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.18M | – |
| Q3 FY2024 | Sep 30, 2024 | $12.02M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$35.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.42M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$45.42M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.05M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.20M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.76M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.10M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.07M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.06M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.30M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.92M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.96M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.04M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.37M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.61M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.52M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.67M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.89M | – |
See a number that looks wrong?